A Phase 1 Open-label Study Evaluating the Pharmacokinetics and Mass Balance of [14C] TAS-205 in Healthy Volunteers
Latest Information Update: 11 Aug 2022
Price :
$35 *
At a glance
- Drugs Pizuglanstat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 04 Aug 2022 Status changed from active, no longer recruiting to completed.
- 13 Aug 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Apr 2021 New trial record